drugset / Trial / NCT06680349
Two Anti-CD20 Regimens for Fibrillary Glomerulonephritis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the clinical and histological effects of two rituximab-based regimens in fibrillary glomerulonephritis.
Timeline
- Start
- 2022-12-01
- Primary completion
- 2024-01-02
- Completion
- 2024-01-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 10 mg/kg | — |
| Subject | Methylprednisolone | Other / unclassified | 15 mg/kg | — |
| Subject | Prednisone | Other / unclassified | 50 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |